v3.26.1
Segment information - Schedule of Financial Data for the Company's Reportable Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Research and development expenses $ (4,747) $ (3,930)
General and administrative expenses (4,019) (7,272)
Net loss before income tax (6,719) (12,887)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Other (58) (114)
General and administrative expenses (4,019) (7,272)
Other segment items 2,047 (1,685)
Net loss before income tax (6,719) (12,887)
Operating Segments [Member] | Setrusumab (BPS-804/UX143) [Member]    
Segment Reporting Information [Line Items]    
Research and development expenses (4,052) (2,244)
Operating Segments [Member] | Alvelestat (MPH-966) [Member]    
Segment Reporting Information [Line Items]    
Research and development expenses (443) (1,365)
Operating Segments [Member] | Etigilimab (MPH-313) [Member]    
Segment Reporting Information [Line Items]    
Research and development expenses $ (194) $ (207)